Pellucid marginal degeneration

This phase 3 trial tests whether a shorter 18-minute ultraviolet (UVA) light exposure works as well as the standard 24-minute exposure during corneal crosslinking for keratoconus and similar conditions. The treatment uses riboflavin (vitamin B2) eye drops followed by UVA light to…

This Phase 3 trial tests a treatment called corneal crosslinking (CXL) for people with Down syndrome who have keratoconus, a condition where the cornea thins and bulges, blurring vision. The procedure uses vitamin B2 eye drops and ultraviolet light to strengthen the cornea. Resea…

This study tests a device that uses riboflavin (vitamin B2) drops and UV light to stiffen the cornea, the clear front part of the eye. It is for people with keratoconus or similar conditions that cause the cornea to bulge and blur vision. The goal is to see if the treatment safel…

This study aims to improve how doctors detect, classify, and treat irregular corneas caused by conditions like keratoconus, dry eye, and corneal scars. Researchers will use a special imaging device called optical coherence tomography (OCT) to get detailed measurements of the corn…